EdgePoint Investment Group Inc. Raises Stake in Twist Bioscience Corporation $TWST

EdgePoint Investment Group Inc. grew its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 71.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,082,319 shares of the company’s stock after acquiring an additional 1,696,377 shares during the quarter. Twist Bioscience comprises approximately 0.9% of EdgePoint Investment Group Inc.’s investment portfolio, making the stock its 22nd biggest position. EdgePoint Investment Group Inc. owned about 0.07% of Twist Bioscience worth $114,876,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TWST. Bridgefront Capital LLC purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $379,000. Algert Global LLC raised its stake in Twist Bioscience by 16.4% during the third quarter. Algert Global LLC now owns 60,301 shares of the company’s stock worth $1,697,000 after purchasing an additional 8,507 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in Twist Bioscience by 117.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 65,449 shares of the company’s stock valued at $1,842,000 after purchasing an additional 35,323 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Twist Bioscience by 34.4% in the 3rd quarter. Lazard Asset Management LLC now owns 78,350 shares of the company’s stock valued at $2,205,000 after purchasing an additional 20,039 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Twist Bioscience by 7.7% in the 3rd quarter. California State Teachers Retirement System now owns 58,345 shares of the company’s stock valued at $1,642,000 after buying an additional 4,158 shares during the period.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $43.28 on Friday. The company’s 50 day simple moving average is $44.94 and its 200-day simple moving average is $35.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -33.81 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. The firm’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a research report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Evercore lifted their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. Finally, Barclays upped their price target on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $45.88.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,001 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $46.58, for a total value of $232,946.58. Following the sale, the chief executive officer owned 869,312 shares in the company, valued at approximately $40,492,552.96. The trade was a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 7,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $45.65, for a total value of $319,550.00. Following the transaction, the chief accounting officer directly owned 58,738 shares in the company, valued at approximately $2,681,389.70. The trade was a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 40,392 shares of company stock valued at $1,840,796 over the last ninety days. 3.08% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.